Contrasting Nanovibronix (FEED) & Its Peers

Nanovibronix (NASDAQ:FEED) is one of 29 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its competitors? We will compare Nanovibronix to related businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Institutional & Insider Ownership

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 5.2% of Nanovibronix shares are owned by company insiders. Comparatively, 18.4% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Nanovibronix and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1	0	0	0	1.00
Nanovibronix Competitors	77	78	158	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 36.23%. Given Nanovibronix’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Nanovibronix has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Nanovibronix and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nanovibronix	$2.56 million	-$3.70 million	-0.06
Nanovibronix Competitors	$58.68 million	-$32.15 million	4.38

Nanovibronix’s competitors have higher revenue, but lower earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Nanovibronix has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Nanovibronix’s competitors have a beta of 1.76, suggesting that their average share price is 76% more volatile than the S&P 500.

Profitability

This table compares Nanovibronix and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-275.12%	-24.78%	-19.24%
Nanovibronix Competitors	-672.41%	-133.75%	-59.01%

Summary

Nanovibronix competitors beat Nanovibronix on 8 of the 13 factors compared.

About Nanovibronix

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.